PA
BVS icon

PharVision Advisers’s Bioventus BVS Stock Holding History

PharVision Advisers’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,302
Closed -$102K – 720
2025
Q3 		$102K Buy
15,302
+5,230
+52% +$36.3K 0.06% 620
2025
Q2 		$66.7K Buy
+10,072
New +$71.4K 0.1% 266

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JIC
Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PharVision Advisers's BVS Position: Q4 2025 in Review

PharVision Advisers sold out of Bioventus (BVS) in Q4 2025, closing a stake of 15,302 shares — an estimated $102K sold.

PharVision Advisers first reported a position in BVS in Q2 2025 and held it in 2 quarters. The position peaked at $102K in Q3 2025. 148 funds tracked by Wall St. Rank hold BVS as of Q4 2025.

  • PharVision Advisers reported no remaining Bioventus position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 15,302 Bioventus shares in Q4 2025, an estimated $102K.
  • PharVision Advisers first reported a position in Bioventus in Q2 2025 and held it in 2 quarters.
  • PharVision Advisers's Bioventus position peaked at $102K in Q3 2025.
  • 148 funds tracked by Wall St. Rank held Bioventus as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.